NeuroN-QI: An Intervention to Promote Preterm Infants' Neurodevelopment

Sponsor
St. Justine's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06087744
Collaborator
(none)
124
1
2
48
2.6

Study Details

Study Description

Brief Summary

NeuroN-QI aims to evaluate the effects of an intervention consisting of periods of: 1) parents/preterm infants skin-to-skin contact and auditory stimulation by the parents's voice and 2) calm without manipulation with olfactory stimulation with breast milk in the incubator/bed both combined with appropriate light and noise levels to promote neurodevelopment preterm infants.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: NeuroN-QI
  • Behavioral: SSC alone
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Effects of a Parent-preterm Proximity and Calm Intervention (NeuroN-QI) on the Neurodevelopment of Preterm Infants: A Randomized Pragmatic Clinical Trial
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2026
Anticipated Study Completion Date :
Oct 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: NeuroN-QI

Randomized dyads in the experimental group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SSC) lasting 2 hours until the age of 36 weeks. Auditory sensory stimulation by mothers or fathers (reading a book) will be carried out during the first 10 minutes during the SSC sessions. The SSC will be followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.

Behavioral: NeuroN-QI
Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.

Active Comparator: SSC alone

Randomized dyads in the control group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SPC) lasting 2 hours until the corrected age of 36 weeks. During these sessions, light and noise levels will not be controlled or accompanied of auditory stimulation. SSC periods will not be followed by a calm and rest period with a olfactory stimulation.

Behavioral: SSC alone
Skin-to-skin contact (SSC) lasting 2 hours

Outcome Measures

Primary Outcome Measures

  1. Neurodevelopment [36 weeks gestational age (GA)]

    Recording with video and coding with Assessment of Behavioral Systems Organization (ABSO) (from Assessment of Preterm Infant Behavior (APIB))

Secondary Outcome Measures

  1. Neurodevelopment [4 months and 18 months]

    Cerebral discontinuity activity vs. activity with EEG

  2. Neurodevelopment [4 months and 18 months]

    Bayley-IIII (Questionnaire)

  3. Parental Stress [Baseline before randomization and every week after until 36 weeks GA]

    Questionnaire - Parental Stress Scale - Neonatal Intensive Care Unit (NICU) (PSS:NICU) - 25 items with a 5-point Likert-type. Minimum value: 25, maximum value: 100. A higher score indicates higher parental stress.

  4. Parental Anxiety [Baseline before randomization and every week after until 36 weeks GA]

    Questionnaire - State-Trait Anxiety Inventory (STAI) - 20 items with a 4-point Likert-type scale. Minimum value: 20; maximum value: 80. A higher score indicates higher anxiety.

  5. Parental sensitivity [4 months ans 18 months]

    Recording through videos and coding with Welch Emotional Connection Screen (WECS) - 4 dimensions: mutual attraction, facial communication, vocal communication and sensitivity/reciprocity are coded on a 9-point scale from 1 to 3. Minimum value 4; maximum value 12. Higher scores indicate a better mother-child emotional connection.

  6. Milk production [Every day in mL until study completion at infants' 36 weeks gestational age.]

    Through diary

  7. Milk consumption [Total in mL until study completion at infants' 36 weeks gestational age.]

    Through charting

Eligibility Criteria

Criteria

Ages Eligible for Study:
24 Weeks to 34 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for preterm infants:
  • born between 24 and 33 6/7 weeks GA;

  • ready for SSC

Inclusion criteria for mothers and fathers:
  • agree to do at least one SSC session/week combined with 10 min of auditory stimulation until 36 weeks of GA of their preterm infant;

  • mothers express breast milk for their preterm infants

For twin births (twin pregnancies), fathers will also be invited to participate in the study, so that both infants can participate in the study.

Exclusion criteria for preterm infants:
  • congenital anomalies or genetic disorders

  • intraventricular hemorrhage > grade II

  • are small for GA defined as birth weight <10th percentile

  • on postnatal day 19 (maximum days targeted for study start)

  • are still receiving analgesics, sedatives, paralyzing agents

  • are under mechanical ventilation

Exclusion criteria mothers and fathers:
  • are aged <18 years;

  • have a physical condition that does not allow the SSC

  • abuse illicit substances or alcohol that could influence stress, anxiety and parent- child interactions

  • feed their preterm infant exclusively with commercial infant formula

  • mothers had a breast surgery that could influence their breast milk production

  • do not speak, read or write in French or in English

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Sainte-Justine Montréal Quebec Canada H3T 1C5

Sponsors and Collaborators

  • St. Justine's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marilyn Aita, Researcher, St. Justine's Hospital
ClinicalTrials.gov Identifier:
NCT06087744
Other Study ID Numbers:
  • MP-21-2023-5375
First Posted:
Oct 18, 2023
Last Update Posted:
Oct 18, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Marilyn Aita, Researcher, St. Justine's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2023